• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. Dec 2004; 63(12): 1538–1543.
Published online Jul 8, 2004. doi:  10.1136/ard.2004.024737
PMCID: PMC1754871

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety

Full Text

The Full Text of this article is available as a PDF (90K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol. 2001 May;13(3):164–169. [PubMed]
  • Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997 May-Jun;15 (Suppl 17):S27–S38. [PubMed]
  • Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20 (Suppl 100):C40–C44. [PubMed]
  • Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255–1259. [PubMed]
  • Camussi G, Albano E, Tetta C, Bussolino F. The molecular action of tumor necrosis factor-alpha. Eur J Biochem. 1991 Nov 15;202(1):3–14. [PubMed]
  • Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. [PubMed]
  • Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. [PubMed]
  • Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000 Apr;27(4):841–850. [PubMed]
  • Weinblatt Michael E, Keystone Edward C, Furst Daniel E, Moreland Larry W, Weisman Michael H, Birbara Charles A, Teoh Leah A, Fischkoff Steven A, Chartash Elliot K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35–45. [PubMed]
  • Furst Daniel E, Schiff Michael H, Fleischmann Roy M, Strand Vibeke, Birbara Charles A, Compagnone Daniele, Fischkoff Steven A, Chartash Elliot K. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563–2571. [PubMed]
  • Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001 Jun;76(6):653–656. [PubMed]
  • Chan ATY, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002 Jan;78(915):47–48. [PMC free article] [PubMed]
  • Doran Michele F, Crowson Cynthia S, Pond Gregory R, O'Fallon W Michael, Gabriel Sherine E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287–2293. [PubMed]
  • Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002 Sep;61(9):793–798. [PMC free article] [PubMed]
  • Phillips Kristine, Husni M Elaine, Karlson Elizabeth W, Coblyn Jonathan S. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum. 2002 Feb;47(1):17–21. [PubMed]
  • Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003 May;42(5):617–621. [PubMed]
  • Ellerin Todd, Rubin Robert H, Weinblatt Michael E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003 Nov;48(11):3013–3022. [PubMed]
  • Lee Jong-Hoon, Slifman Nancy R, Gershon Sharon K, Edwards Evelyne T, Schwieterman William D, Siegel Jeffrey N, Wise Robert P, Brown S Lori, Udall John N, Jr, Braun M Miles. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002 Oct;46(10):2565–2570. [PubMed]
  • Slifman Nancy R, Gershon Sharon K, Lee Jong-Hoon, Edwards Evelyne T, Braun M Miles. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003 Feb;48(2):319–324. [PubMed]
  • Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 2002 Aug;41(8):951–952. [PubMed]
  • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. [PubMed]
  • Temekonidis TI, Georgiadis AN, Alamanos Y, Bougias DV, Voulgari PV, Drosos AA. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis. 2002 Sep;61(9):822–825. [PMC free article] [PubMed]
  • Vonkeman HE, van der Valk PDLPM, Mulder L, van de Laar MAFJ. Fatale miliaire tuberculose tijdens behandeling met infliximab. Ned Tijdschr Geneeskd. 2002 Jun 22;146(25):1196–1199. [PubMed]
  • Shergy William J, Isern Reuben A, Cooley David A, Harshbarger John L, Huffstutter J Eugene, Hughes Gordon M, Spencer-Smith Elizabeth A, Goldman Allan L, Roth Sanford H, Toder J Scott, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002 Apr;29(4):667–677. [PubMed]
  • Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis. 2004 Feb;63(2):144–148. [PMC free article] [PubMed]
  • van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JPJ, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003 Dec;29(12):2327–2329. [PubMed]
  • Rovere Querini P, Vecellio M, Sabbadini MG, Ciboddo G. Miliary tuberculosis after biological therapy for rheumatoid arthritis. Rheumatology (Oxford) 2002 Feb;41(2):231–231. [PubMed]
  • Mayordomo Lucia, Marenco Jose Luis, Gomez-Mateos Jesus, Rejon Eduardo. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol. 2002;31(1):44–45. [PubMed]
  • Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J. 2002 Nov;71(2):101–105. [PMC free article] [PubMed]
  • Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford) 2003 Jul;42(7):901–902. [PubMed]
  • Parra Ruiz Jorge, Ortego Centeno Norberto, Raya Alvarez Enrique. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol. 2003 Jul;30(7):1657–1658. [PubMed]
  • Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003 Jul-Aug;21(4):526–526. [PubMed]
  • Derk CT, DeHoratius RJ. Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis. 2003 Apr;62(4):372–372. [PMC free article] [PubMed]
  • Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, Sekikawa K, Sugawara I. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest. 1999 Apr;79(4):379–386. [PubMed]
  • Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989 Mar 10;56(5):731–740. [PubMed]
  • Gardam Michael A, Keystone Edward C, Menzies Richard, Manners Steven, Skamene Emil, Long Richard, Vinh Donald C. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003 Mar;3(3):148–155. [PubMed]
  • Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, Kim TY, Yoo DH. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002 Mar-Apr;20(2):127–132. [PubMed]
  • Carmona Loreto, Hernández-García César, Vadillo Cristina, Pato Esperanza, Balsa Alejandro, González-Alvaro Isidoro, Belmonte Miguel Angel, Tena Xavier, Sanmartí Raimon. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Jul;30(7):1436–1439. [PubMed]
  • Gómez-Reino Juan J, Carmona Loreto, Valverde Vicente Rodríguez, Mola Emilio Martín, Montero Maria Dolores. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003 Aug;48(8):2122–2127. [PubMed]
  • Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993 Jun 2;269(21):2765–2768. [PubMed]
  • Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862–2869. [PubMed]
  • Selmaj KW. Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann Rheum Dis. 2000 Nov;59 (Suppl 1):i94–102. [PMC free article] [PubMed]
  • Lock C, Oksenberg J, Steinman L. The role of TNFalpha and lymphotoxin in demyelinating disease. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I121–I128. [PMC free article] [PubMed]
  • Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001 Nov 27;57(10):1885–1888. [PubMed]
  • Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. [PubMed]
  • Brand CA, Rowley MJ, Tait BD, Muirden KD, Whittingham SF. Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features. Ann Rheum Dis. 1992 Feb;51(2):173–176. [PMC free article] [PubMed]
  • Cohen MG, Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis. 1987 Nov;46(11):853–858. [PMC free article] [PubMed]
  • Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996 Feb 15;93(4):704–711. [PubMed]
  • Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999 Jun 29;99(25):3224–3226. [PubMed]
  • Anker Stefan D, Coats Andrew J S. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002 Dec;86(2-3):123–130. [PubMed]
  • Chung Eugene S, Packer Milton, Lo Kim Hung, Fasanmade Adedigbo A, Willerson James T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003 Jul 1;107(25):3133–3140. [PubMed]
  • Kwon Hyon J, Coté Timothy R, Cuffe Michael S, Kramer Judith M, Braun M Miles. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807–811. [PubMed]
  • de' Clari Franco, Salani I, Safwan E, Giannacco A. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation. 2002 May 28;105(21):E183–E183. [PubMed]
  • Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J. 2000 Dec;72(12):517–519. [PubMed]
  • Watson Douglas J, Rhodes Thomas, Guess Harry A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003 Jun;30(6):1196–1202. [PubMed]
  • Solomon Daniel H, Karlson Elizabeth W, Rimm Eric B, Cannuscio Carolyn C, Mandl Lisa A, Manson JoAnn E, Stampfer Meir J, Curhan Gary C. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303–1307. [PubMed]
  • Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol. 1984 May;23(2):92–99. [PubMed]
  • Symmons Deborah P M, Silman Alan J. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 2004 Jun;50(6):1703–1706. [PubMed]
  • Marchesoni A, Arreghini M, Panni B, Battafarano N, Uziel L. Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. Rheumatology (Oxford) 2003 Jan;42(1):193–194. [PubMed]
  • Kuruvilla John, Leitch Heather A, Vickars Linda M, Galbraith Paul F, Li Charles H, Al-Saab Saad, Naiman Sheldon C. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol. 2003 Nov;71(5):396–398. [PubMed]
  • Cursiefen Claus, Grunke Mathias, Dechant Claudia, Antoni Christian, Jünemann Anselm, Holbach Leonard M. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy. Am J Ophthalmol. 2002 Aug;134(2):270–271. [PubMed]
  • True David G, Penmetcha Mohan, Peckham Steven J. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol. 2002 Jul;29(7):1561–1563. [PubMed]
  • Sawalha Amr H, Lutz Brock D, Chaudhary Nadeem A, Kern William, Harley John B, Greenfield Ronald A. Panniculitis: a presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis. J Clin Rheumatol. 2003 Aug;9(4):259–262. [PubMed]
  • Nakelchik Masha, Mangino Julie E. Reactivation of histoplasmosis after treatment with infliximab. Am J Med. 2002 Jan;112(1):78–78. [PubMed]
  • Wood Karen L, Hage Chadi A, Knox Kenneth S, Kleiman Martin B, Sannuti Aruna, Day Richard B, Wheat L Joseph, Twigg Homer L., 3rd Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003 May 1;167(9):1279–1282. [PubMed]
  • Glück T, Linde H-J, Schölmerich J, Müller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002 Aug;46(8):2255–2257. [PubMed]
  • Harney S, O'Shea FD, FitzGerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis. Ann Rheum Dis. 2002 Jul;61(7):653–654. [PMC free article] [PubMed]
  • Hage Chadi A, Wood Karen L, Winer-Muram Helen T, Wilson Stephen J, Sarosi George, Knox Kenneth S. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003 Dec;124(6):2395–2397. [PubMed]
  • Chopra Nagesh, Kirschenbaum Abram E, Widman David. Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol. 2002 Oct;8(5):265–268. [PubMed]
  • Benz Matthew S, Glaser Joel S, Davis Janet L. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol. 2003 Apr;135(4):551–553. [PubMed]
  • Smith Davey, Letendre Scott. Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med. 2002 Jan 15;136(2):174–174. [PubMed]
  • Carter JD, Kanik KS, Valeriano J. Neck mass in a rheumatoid arthritis patient taking etanercept. J Clin Rheumatol. 2000 Apr;6(2):80–81. [PubMed]
  • van der Laken CJ, Lems WF, van Soesbergen RM, van der Sande JJ, Dijkmans BAC. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum. 2003 Jan;48(1):269–270. [PubMed]
  • Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001 Jul 7;358(9275):24–29. [PubMed]
  • ten Tusscher Marcel P M, Jacobs Piet J C, Busch Michiel J W M, de Graaf Linda, Diemont Willem L. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ. 2003 Mar 15;326(7389):579–579. [PMC free article] [PubMed]
  • Hrycaj P, Korczowska I, Łacki JK. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) 2003 May;42(5):702–703. [PubMed]
  • Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum. 2001 Aug;44(8):1966–1968. [PubMed]
  • Kent Peter D, Davis John M, 3rd, Davis Mark D P, Matteson Eric L. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum. 2002 Aug;46(8):2257–2259. [PubMed]
  • McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002 Jan;41(1):116–117. [PubMed]
  • Jarrett Stephen J, Cunnane Gaye, Conaghan Philip G, Bingham Sarah J, Buch Maya H, Quinn Mark A, Emery Paul. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003 Oct;30(10):2287–2291. [PubMed]
  • Fitzcharles Mary-Ann, Clayton Denise, Ménard Henri André The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol. 2002 Dec;29(12):2525–2530. [PubMed]
  • Walsh DA, Wilson D. Post-mortem collection of human joint tissues for research. Rheumatology (Oxford) 2003 Dec;42(12):1556–1558. [PubMed]
  • Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11(11):753–755. [PubMed]
  • Debandt M, Vittecoq O, Descamps V, Le Loët X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003 Feb;22(1):56–61. [PubMed]
  • Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000 Aug;27(8):2041–2044. [PubMed]
  • Cunnane Gaye, Warnock Martha, Fye Kenneth H, Daikh David I. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002 Aug;47(4):445–449. [PubMed]
  • Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 2002 Feb;146(2):334–335. [PubMed]
  • Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med. 1999 Oct 19;131(8):634–634. [PubMed]
  • Soliotis F, Glover M, Jawad ASM. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis. 2002 Sep;61(9):850–851. [PMC free article] [PubMed]
  • Berthelot J-M, Glemarec J, Maugars Y, Prost A. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis. Rheumatology (Oxford) 2002 Jun;41(6):703–705. [PubMed]
  • Caramaschi P, Biasi D, Carletto A, Bambara LM. Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol. 2003 Jan-Feb;21(1):136–137. [PubMed]
  • Andrés E, Limbach F-X, Goichot B, Sibilia J. Silent thyroiditis associated with etanercept in rheumatoid arthritis. Ann Rheum Dis. 2002 Jun;61(6):565–565. [PMC free article] [PubMed]
  • Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001 Nov;40(11):1317–1319. [PubMed]
  • Shakoor Najia, Michalska Margaret, Harris Charlotte A, Block Joel A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002 Feb 16;359(9306):579–580. [PubMed]
  • Cairns AP, Duncan MKJ, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002 Nov;61(11):1031–1032. [PMC free article] [PubMed]
  • Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MHA. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003 Nov;28(6):604–607. [PubMed]
  • Brown S Lori, Greene Mark H, Gershon Sharon K, Edwards Evelyne T, Braun M Miles. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 Dec;46(12):3151–3158. [PubMed]
  • Aouba A, De Bandt M, Aslangul E, Atkhen N, Patri B. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) 2003 Jun;42(6):800–802. [PubMed]
  • Kremer Joel M, Weinblatt Michael E, Bankhurst Arthur D, Bulpitt Ken J, Fleischmann Roy M, Jackson Christopher G, Atkins Kelly M, Feng Anyang, Burge Daniel J. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003 Jun;48(6):1493–1499. [PubMed]
  • Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links